Marshall Wace LLP grew its position in BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating) by 31.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 502,350 shares of the company’s stock after acquiring an additional 120,000 shares during the period. Marshall Wace LLP’s holdings in BioPlus Acquisition were worth $5,049,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of BIOS. Goldman Sachs Group Inc. acquired a new position in shares of BioPlus Acquisition in the first quarter worth about $8,152,000. Polar Asset Management Partners Inc. acquired a new position in shares of BioPlus Acquisition during the 1st quarter worth about $7,410,000. Starboard Value LP acquired a new position in shares of BioPlus Acquisition during the 1st quarter worth about $6,098,000. Spring Creek Capital LLC acquired a new position in shares of BioPlus Acquisition during the 1st quarter worth about $4,940,000. Finally, Radcliffe Capital Management L.P. acquired a new position in shares of BioPlus Acquisition during the 1st quarter worth about $3,953,000. Institutional investors and hedge funds own 72.81% of the company’s stock.
BioPlus Acquisition Stock Performance
BIOS opened at $10.40 on Tuesday. BioPlus Acquisition Corp. has a twelve month low of $9.85 and a twelve month high of $10.43. The company has a 50-day moving average price of $10.33 and a 200 day moving average price of $10.19.
BioPlus Acquisition Company Profile
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
- Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOS)
- First Republic: First Rate Risk or Time To Buy?
- These Hedge Funds Are Getting Crushed By SVB
- Buy The Dip In The Charles Schwab Corporation
- ZIM Integrated Shipping Services: Up 15% But Don’t Chase It
- FedEx Is A Buy Going Into Earnings
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating).
Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.